

RESEARCH

Open Access

Development of guidelines for the surveillance of invasive mosquitoes in Europe

Francis Schaffner^{1*}, Romeo Bellini², Dušan Petrić³, Ernst-Jan Scholte⁴, Hervé Zeller⁵
and Laurence Marrama Rakotoarivony^{5*}

Abstract

Background: The recent notifications of autochthonous cases of dengue and chikungunya in Europe prove that the region is vulnerable to these diseases in areas where known mosquito vectors (*Aedes albopictus* and *Aedes aegypti*) are present. Strengthening surveillance of these species as well as other invasive container-breeding aedine mosquito species such as *Aedes atropalpus*, *Aedes japonicus*, *Aedes koreicus* and *Aedes triseriatus* is therefore required. In order to support and harmonize surveillance activities in Europe, the European Centre for Disease Prevention and Control (ECDC) launched the production of 'Guidelines for the surveillance of invasive mosquitoes in Europe'. This article describes these guidelines in the context of the key issues surrounding invasive mosquitoes surveillance in Europe.

Methods: Based on an open call for tender, ECDC granted a pan-European expert team to write the guidelines draft. Its content is founded on published and grey literature, contractor's expert knowledge, as well as appropriate field missions. Entomologists, public health experts and end users from 17 EU/EEA and neighbouring countries contributed to a reviewing and validation process. The final version of the guidelines was edited by ECDC (Additional file 1).

Results: The guidelines describe all procedures to be applied for the surveillance of invasive mosquito species. The first part addresses strategic issues and options to be taken by the stakeholders for the decision-making process, according to the aim and scope of surveillance, its organisation and management. As the strategy to be developed needs to be adapted to the local situation, three likely scenarios are proposed. The second part addresses all operational issues and suggests options for the activities to be implemented, *i.e.* key procedures for field surveillance of invasive mosquito species, methods of identification of these mosquitoes, key and optional procedures for field collection of population parameters, pathogen screening, and environmental parameters. In addition, methods for data management and analysis are recommended, as well as strategies for data dissemination and mapping. Finally, the third part provides information and support for cost estimates of the planned programmes and for the evaluation of the applied surveillance process.

Conclusion: The 'Guidelines for the surveillance of invasive mosquitoes in Europe' aim at supporting the implementation of tailored surveillance of invasive mosquito species of public health importance. They are intended to provide support to professionals involved in mosquito surveillance or control, decision/policy makers, stakeholders in public health and non-experts in mosquito surveillance. Surveillance also aims to support control of mosquito-borne diseases, including integrated vector control, and the guidelines are therefore part of a tool set for managing mosquito-borne disease risk in Europe.

Keywords: Invasive mosquitoes, Aedes, Surveillance, Monitoring, Vector, Dengue, Chikungunya, Europe, Guidelines

* Correspondence: fschaffner@avia-gis.com; Laurence.Marrama@ecdc.europa.eu

¹Avia-GIS, Risschotlei 33, B-2980 Zoersel, Belgium

⁵ECDC, European Centre for Disease Prevention and Control, Tomtebodavägen 11A, 17183 Stockholm, Sweden

Full list of author information is available at the end of the article

Background

Vector-borne diseases are a specific group of infections that present a (re-)emerging threat to Europe and therefore require particular attention [1]. The recent notifications of autochthonous transmission of dengue and chikungunya fevers in Europe [2-5], and the outbreak of dengue in Madeira [6], demonstrate the region's vulnerability to these diseases in areas where an effective vector, *Aedes albopictus* (Skuse) (Figure 1) or *Aedes aegypti* Linnaeus, is present. Strengthening the surveillance of these two species as well as the other exotic and invasive mosquito species (Table 1), *Aedes atropalpus* (Coquillett), *Aedes japonicus japonicus* (Theobald), *Aedes koreicus* (Edwards) and *Aedes triseriatus* (Say) in areas at risk of importation or spread of mosquitoes and risk of virus transmission is therefore required [1]. This is particularly important in the context of environmental changes in, for example, land cover or weather patterns that might lead to an increase of vector populations, vector-host contact and virus amplification [7-9].

Early detection of invasive mosquito species (IMS) enables appropriate and timely response measures and subsequent prevention of mosquito-borne disease (MBD) [10]. In addition, however, in areas where IMS have become established, timely surveillance of their abundance and spread is needed to assess the risk of pathogen transmission to humans [1]. In order to encourage the Member States to collect appropriate data on IMS in the field and further harmonise surveillance procedures within Europe, the European Centre for Disease Prevention and Control (ECDC) launched the production of 'Guidelines for the surveillance of invasive mosquitoes in Europe' as part of a toolset for assessing and controlling a number of risks posed by IMS and MBDs (Figure 2). This document describes the guidelines in the context of the key issues surrounding IMS surveillance in Europe.



Figure 1 *Aedes albopictus*, female. Source: F.Schaffner/ECDC.

Methods

The mosquito species considered here are all exotic species that have been introduced into Europe in recent decades and have proven or are suspected to be invasive.

The proposed surveillance methods are applicable in the whole of geographical Europe (all European Union/European Economic Area and neighbouring countries), including European Union Outermost Regions, but they are not suitable for the Overseas Countries and Territories, which have different vector species, diseases, environment, and climate to the European continent.

'Surveillance' (as opposed to 'monitoring'), is defined here as a set of procedures developed in response to a recognised risk and carried out to support subsequent actions. Surveillance of mosquito vectors in Europe can therefore contribute to a global plan for risk assessment and management of MBDs (Figures 2, Figure 3).

Development of these guidelines

In order to produce a draft version of these guidelines, ECDC launched an open call for tenders on 6 April 2011 (OJ/06/04/2011-PROC/2011/023). After a thorough evaluation of all applications, a contract was signed with the authors, representing a pan-European spectrum of complementary experience and knowledge in mosquito surveillance as applied to IMS.

The guidelines are based on a review of published and grey literature as well as on field experience of the contract team and external experts from two major European networks: VBORNET (the European network of medical entomologists and public health experts, www.vbornet.eu); and EMCA-AIM-WG (the *Aedes albopictus* and other invasive mosquitoes Working Group of the European Mosquito Control Association, <http://www.emca-online.eu>). Moreover, in order to obtain up-to-date information about mosquito surveillance activities in Europe, two missions were performed in Spain and Portugal: Spain has over five years experience of IMS surveillance, while Portugal has only recently implemented mosquito monitoring with little focus on IMS. An additional mission was carried out in the north-eastern United States (interviewing research units and mosquito control abatements from Connecticut, Michigan, and New Jersey) where some vectors, pathogens, and consequently surveillance strategies are different from those implemented in Europe.

A draft version of the guideline document was reviewed during an *ad hoc* meeting at ECDC in Stockholm. Entomologists, public health experts and end users from 17 EU/EEA and neighbouring countries (Albania, Austria, Belgium, Bulgaria, Croatia, Denmark, France, Germany, Greece, Italy, Portugal, Romania, Serbia, Spain, Switzerland, the Netherlands, and the United Kingdom) took part in the meeting to review, improve and agree on the guidelines [11]. As an outcome of this process, a final version

Table 1 Mosquito species names

Traditional name (1906–2000)	Reinert et al. 2004	Reinert et al. 2006
<i>Aedes (Stegomyia) aegypti</i>	<i>Stegomyia aegypti</i>	<i>St. (Ste.) aegypti*</i>
<i>Ae. (Ste.) albopictus</i>	<i>St. albopicta</i>	
<i>Ae. (Ochlerotatus) atropalpus</i>	<i>Ochlerotatus (Och.) atropalpus</i>	<i>GeorceCraigius (Gec.) atropalpus</i>
<i>Ae. (Finlaya) japonicus</i>	<i>Oc. (Fin.) japonicus</i>	<i>Hulecoeteomyia japonica</i>
<i>Ae. (Fin.) koreicus</i>	<i>Oc. (Fin.) koreicus</i>	<i>Hl. koreica</i>
<i>Ae. (Protomacleaya) triseriatus</i>	<i>Oc. (Pro.) triseriatus</i>	

Major generic changes within the tribe Aedini were recently published [12-14], leading to scientific debate and two or more names being simultaneously used for a single taxon. In this article we use the traditional names [15,16], with alternate names shown in the table. * Subgenus *Stegomyia* re-defined in [17].

of the guidelines was edited by ECDC (see Additional file 1).

Results and discussion

The guidelines

The guidelines provide accurate information and technical support for focused surveillance activities and data collection in the field. They also provide cost estimates

and suggest adaptations according to the local context and the evolution of the epidemiological situation. They are intended to describe all procedures to be applied to the surveillance of IMS.

The first part addresses strategic issues and steps to be taken by the stakeholders for the decision-making process. According to the aim and scope of surveillance, advice is provided to define the organisation and management of





Figure 2 Procedures and main issues of invasive mosquito species and mosquito-borne disease surveillance in Europe. Green rounded rectangles show sources of information and alerts on risks for IMS and MBD that justify surveillance; part of it is performed within VBORNET, the European network of medical entomologists and public health experts (upper light green rectangle). These guidelines focus and develop the central part (central yellow rectangle). The left part is already addressed within the WHO guidelines (light blue rectangle), whereas the lower part is dealt with by the EMCA/WHO initiative on guidelines (dark blue rectangle). Blue rounded rectangles show procedures for surveillance (light blue) and control (dark blue) of IMS. Red rounded rectangles show procedures that are addressed within MBDs risk plans alongside IMS surveillance and control. *WHO Guidelines* (www.who.int/ihr/en): In the context of the application of the International Health Regulations (IHR 2005), WHO aims to strengthen national capacities by developing and updating guidelines and tools on vector surveillance and control. Thus, a web-based global point of entry (PoE) vector identification platform is under development, as well as a 'Handbook on vector surveillance and control at points of entry'. This handbook focuses on actions that can be performed at PoE and on conveyances, containers, cargo, postal parcels and baggage. It considers all vector species (including mosquitoes) relevant to major MBDs. *EMCA/WHO Guidelines*: EMCA and WHO European Region have recently launched an initiative to develop 'Guidelines for the control of invasive mosquitoes and associated vector-borne diseases on the European continent', based on pan-European consultations. The first deliverable will be a strategy document with special emphasis on control issues.



the process, as well as the surveillance strategy to be developed. Three likely scenarios are proposed:

- Scenario 1 – No established IMS: There is a risk of introduction and establishment of IMS but this has not yet been reported. Surveillance activities are designed to detect possible introduction and establishment of IMS at specific points of entry.
- Scenario 2 – Locally established IMS: An IMS population is locally established in a small area, but with no evidence of spreading. Surveillance aims to quantify establishment and detect possible spread of IMS.
- Scenario 3 – Widely established IMS: At least one IMS population has colonised a large area by spreading locally. Surveillance aims to assess IMS population abundance and dynamics.

The risk estimate here is based on presence and abundance of IMS, not on the likelihood of transmission of MBDs. If the country already faces an outbreak of a MBD, then surveillance activities may need to be extended/strengthened, according to complementary guidance for the surveillance of MBDs and control of vectors and MBDs.

The second part addresses all operational issues and steps for the activities to be implemented, *i.e.* key procedures for field surveillance of IMS, methods of identification of IMS, key and optional procedures for field collection of population parameters, pathogen screening, and evaluation of environmental parameters. This part also recommends methods for data management and analysis, as well as strategies for data dissemination and mapping. Practical information is given in annexes, tailored to different audiences, *e.g.* general information on mosquito biology for non-entomologists, original mosquito identification keys for entomologists, practical tips for implementing trapping activities for field technicians.

Finally, the third part provides cost estimates for the planned programmes and sets out the procedures needed to evaluate the surveillance process. It aims at supporting planning and cost estimation prior to surveillance implementation, and at promoting surveillance evaluation and improvement/readjustment of the procedures.

The guidelines contribute to the harmonisation of surveillance methods and information records at the European level so that data and experience from different countries/areas can be compared over time. They are intended to provide support to professionals involved in implementing IMS surveillance or control; to decision- and policy-makers and stakeholders in public health; and also to non-experts in mosquito surveillance and control.

Why survey mosquitoes in Europe?

Mosquitoes may be of public health relevance either when they transmit disease to humans, or when they occur in

sufficient numbers to cause a nuisance. Both indigenous and invasive mosquito species comprise efficient vectors of pathogens (*e.g.* the Asian tiger mosquito, *Ae. albopictus*, is competent to transmit at least 22 arboviruses, and the common house mosquito *Culex pipiens pipiens* at least 6 arboviruses) as demonstrated by the recent outbreaks of chikungunya, dengue, and West Nile fevers in the Mediterranean basin [6,18,19]. In addition to viruses, mosquitoes may transmit malaria parasites (vector species belonging exclusively to the genus *Anopheles*) and dirofilaria worms in Europe. Indeed, the rapid spread of *Ae. albopictus* throughout Italy is likely to have broadened the range of *Dirofilaria immitis* and *D. repens* to include southern regions not previously infected despite the presence of *Culex pipiens pipiens*, which is considered the main indigenous vector of both *Dirofilaria* spp. in Europe [20]. The sympatric occurrence of both vectors, with both diurnal and nocturnal biting activities, may further enhance the risk of transmission to dogs and humans in many parts of Europe [20]. In recent decades, human contact with mosquitoes has become more frequent as suburbs that sprawl into previously undisturbed natural areas provide a greater number and variety of mosquito breeding places than do inner-city areas [21]. In addition, urbanised areas are facing invasion by container-breeding mosquitoes such as *Ae. albopictus* which has an aggressive nuisance behaviour during the day when females are seeking blood meals from humans and domestic animals.

Why focus on invasive mosquitoes?

IMS are defined by their ability to colonise new territories and to cause or to be likely to cause harm to the economy, environment, or human health [22]. Human activities are the primary means of IMS introduction. A considerable increase in the spread of IMS has been observed within Europe since the late 1990s, since then *Ae. albopictus* has continuously expanded its distribution (Figure 4) and several other container-breeding *Aedes* species have been reported from new countries every year (Figure 5; details about successive introductions and spread in Europe are given in [18]). To date, *Ae. albopictus* has colonised most Mediterranean countries, and the Asian bush mosquito *Ae. japonicus* is spreading widely in Central Europe. Two other species, *Ae. atropalpus* and *Ae. koreicus*, have been introduced on several occasions, leading to the establishment of populations at few foci. *Aedes triseriatus* was intercepted at a point of entry, and its establishment was prevented by the implementation of immediate control measures. Finally, the yellow fever mosquito *Ae. aegypti*, which had been introduced into Europe during the 17th-19th centuries existed in coastal areas of southern Europe until its disappearance during the 20th century, probably linked to malaria vector control activities and/or urbanisation and improvement of hygiene, especially in water-




Figure 4 Spread of the Asian tiger mosquito *Ae. albopictus* within Europe, 1995–2012. Red mapping units (territorial units for statistics NUTS 3) = presence; grey units = absence or no available information. The figure has been adjusted and updated compared to the figure given in the guidelines.

supply (piped water). This species has now returned, having recently become established on Madeira as well as around the Black Sea coast (Russia, Abkhazia, Georgia). These invasive mosquito species are well adapted to anthropogenic settings where they exploit the abundant sources of feeding, resting places and larval breeding sites (mainly man-made water containers) [18]. They may also reduce biodiversity as they outcompete native mosquito species, but the main hazard they pose is the threat to both human and animal health.

Economic and social issues


A considerable amount of money is invested in reducing the nuisance caused by mosquitoes in Europe, mainly in tourist regions around the Mediterranean Sea, but also in flood plains (e.g. Danube, Po, Rhine, or Rhone valleys) and irrigated agricultural areas (e.g. northern Italy, northern Greece) [23]. Mosquito control is most often managed by public agencies implementing medium-term programmes. The arrival of IMS in cities and peri-urban areas can affect public perception of the effectiveness of control programmes already in place. Also control methods must be adapted to the mosquito species, as controlling mosquitoes in containers around human settlements is clearly different to controlling cohorts of flood plain/marshland mosquitoes, in terms of available techniques, equipment, and biocides. In addition, higher suppression efficiency will be expected for vector control during an outbreak

compared to control of biting nuisance in a MBD-free context. Indeed, different types of organisations may be involved for different mosquito types. Local government and environmental agencies usually deal with nuisance species, whereas state and public health units are involved in the control of species that transmit pathogens.

Epidemics of MBDs may also have considerable economic impact. A burden of disease analysis performed on the chikungunya epidemic on La Réunion island in the Indian Ocean (2005–2006, 204,000 cases) estimated the total cost of medical expenses at 43.9 million euros, of which 60% was attributable to direct medical costs and 40% to the disease related loss of productivity [24]. This represents 56.10 euros per island inhabitant over two years. Besides medical costs, similarly high expenditures were involved in combating the disease (including vector control measures). These costs can be compared to cost of activities currently supported by the Emilia-Romagna region of Italy, where 5–6 million euros are spent yearly on a prevention plan for dengue and chikungunya (including the direct costs associated with surveillance, control and information management) [25]. This represents approximately 1.4 euros per person in the area at risk.

Current impact of MBDs and threat for the future

Although MBDs (Table 2) currently represent a lower disease burden in temperate than in tropical regions where they have a substantial impact on the countries' socio-economic development, there have always been both



endemic and epidemic autochthonous MBDs in Europe. However, mosquitoes introduced into the area may increase risk to human health by (i) concurrently harbouring novel pathogens, (ii) transmitting native pathogens, or (iii) transmitting novel pathogens that were independently introduced [26].

In certain areas, IMS may remain undetected for a while, as for *Ae. japonicus* in Switzerland, where a first field investigation triggered by a citizen complaint revealed a colonised area of approximately 1,400 km², suggesting that the species had been unnoticed for several years [27]. *Aedes albopictus* was present in Albania and Italy for 30 and 17 years,

respectively, before the first outbreak of MBD attributed to this mosquito was reported in Italy. In France, however, autochthonous cases of chikungunya and dengue were detected only four years after the species was established. This suggests that the global context is becoming more favourable to pathogen introduction (e.g. frequency and intensity of epidemics in dengue-endemic areas) and that the local conditions that make the transmission of diseases carried by IMS possible are now frequently found in Europe. This is correlated with the vectorial capacity of the established mosquito populations and the frequency of vector-host contact [28]. Changes in eco-systems, land

Table 2 Important mosquito-borne pathogens that cause disease in humans

Arboviruses	Transmission in Europe	Important vectors to human
Chikungunya	Italy 2007; France 2010	<i>Ae. aegypti</i> , <i>Ae. albopictus</i>
Dengue 1–4	Until early 20th century in southern Europe; Croatia and France 2010, Portugal (Madeira) 2012	<i>Ae. aegypti</i> , <i>Ae. albopictus</i>
Eastern equine encephalitis, La Crosse encephalitis, Rift Valley fever	–	<i>Aedes</i> spp., <i>Culex</i> spp.
Japanese encephalitis, Murray Valley encephalitis, St Louis encephalitis, Ross River fever, Venezuelan equine encephalitis, Western equine encephalitis	–	<i>Culex</i> spp.
Sindbis	Endemic in northern Europe	<i>Ae. cinereus</i> , <i>Cx. pipiens</i>
West Nile	Endemic in southern Europe	<i>Cx. modestus</i> , <i>Cx. pipiens</i> , <i>Cx. perexiguus</i>
Yellow fever	Until 19th century, mainly in ports and occasionally inland in southern Europe	<i>Ae. aegypti</i> , <i>Ae. africanus</i> , <i>Haemagogus</i> spp.
Plasmodium protozoa		
Malaria	Endemic until mid-20th century; since then sporadic cases; epidemic in Greece 2011, 2012	<i>Anopheles</i> spp.

cover, human behaviour, and climate may impact MBD transmission [8,29]. Some of the factors affect several steps of the transmission cycle: for example, weather conditions may have a direct influence not only on the pathogen itself (*i.e.* higher temperatures allow a faster replication / dissemination of the pathogen in the mosquito) but also affect the vector's reproduction, activity and survival [7,9,30]. These relationships can be used to extrapolate the future possible distribution of a mosquito species based on its ecological requirements and projected scenarios of climate change [31-34]. However, so far, human-induced environmental changes combined with globalisation and absence of or inefficient public health measures have been shown to be the primary driving forces for the emergence and global spread of dengue in the past 40 years [35].

Conclusions

Mosquito-borne diseases are (re-)emerging threats to Europe. The collection of information and data on insect vectors are crucial to understand the levels of risk that countries face, and to define the actions that need to be taken. The 'Guidelines for the surveillance of invasive mosquitoes in Europe' aim to support the implementation of tailored surveillance of IMS of public health importance. They provide accurate information and technical support for focused field data collection, proposing adaptations dictated by the local context and the epidemiological situation, and taking into account estimated costs. They may also contribute to harmonising surveillance methods and information records at the European level so that data from different countries/areas can be compared over time and between different areas. They are also intended to provide support to non-experts in

mosquito surveillance, stakeholders in public health, decision/policy makers, and professionals involved in implementing IMS surveillance or control.

Currently, the targeted mosquito species are all exotic invasive *Aedes* species that have been reported as introduced into Europe to date, including *Ae. aegypti*, *Ae. albopictus*, *Ae. atropalpus*, *Ae. japonicus*, *Ae. koreicus*, and *Ae. triseriatus*. They share the common traits of being container-breeding species, invasive, anthropophilic, and showing significant vectorial capacity. Of the range of pathogens that IMS can transmit, dengue and chikungunya are considered as the main threats to human health, and have been locally transmitted by *Ae. aegypti* and *Ae. albopictus* in Europe and outermost regions. Threats to animal health and to the environment (particularly to biodiversity) can also be addressed by adapting the surveillance methods described in these guidelines. The proposed methods are applicable in the whole of geographical Europe, including European Union Outermost Regions, but not Overseas Countries and Territories.

Surveillance of IMS aims to support MBDs control, including integrated vector control. Assessing and managing the risk of introduced MBDs that have become established in Europe is now a necessity and should also become a priority, in particular in countries where *Ae. albopictus* and/or other IMS are established. The guidelines are therefore part of a tool set for managing MBD risk in Europe. A first evaluation of these guidelines has been performed in Belgium within a pilot study implemented in 2012 and results will be published elsewhere. Further updates are scheduled for three-year intervals, or whenever a major change in vector fauna or MBD risk occurs.

Additional file

Additional file 1: Content: ECDC guidelines for the surveillance of invasive mosquitoes in Europe; Full content.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

All authors contributed to writing the manuscript. LMR managed the production of guidelines, FS co-ordinated the writing phase. FS, RB, DP, and EJS wrote the guidelines, FS produced the figures. LMR and HZ performed the day-to-day reviewing and organised the internal (ECDC) and external reviewing process, and the editorial work at ECDC (Additional file 1). All authors read and approved the final version of the manuscript.

Acknowledgements

ECDC and the authors are grateful to all experts who contributed to the elaboration of these guidelines, in particular for their welcome during the field missions in Portugal, Spain, and USA, and for their contributions to the reviewing process. Special acknowledgments are due to the VBORNET consortium and experts for Figure 5, to Dr Els Ducheyne for Figure 4, and to Dr Willy Wint for the English editorial work.

Author details

¹Avia-GIS, Risschotlei 33, B-2980 Zoersel, Belgium. ²Centro Agricoltura Ambiente "G. Nicoli", Via Argini Nord 3351, 40014 Crevalcore, Italy. ³University of Novi Sad, Faculty of Agriculture, Laboratory for Medical Entomology, Trg D. Obradovića 8, 21000 Novi Sad, Serbia. ⁴National Centre for Monitoring of Vectors, Dutch Food and Consumer Product Safety Authority (NVWA), Geertjesweg 15, P.O. Box 9102, 6700, HC Wageningen, The Netherlands. ⁵ECDC, European Centre for Disease Prevention and Control, Tomtebodavägen 11A, 17183 Stockholm, Sweden.

Received: 15 April 2013 Accepted: 13 July 2013

Published: 18 July 2013

References

1. European Centre for Disease Prevention and Control (ECDC): *Consultation on mosquito-borne disease transmission risk in Europe*. Paris, 26 November 2010, ECDC Meeting Report. Stockholm: ECDC; 2011. http://ecdc.europa.eu/en/publications/Publications/1102_MER_Consultation_on_%20mosquito-borne_diseases.pdf.
2. Angelini R, Finarelli AC, Angelini P, Po C, Petropulacos K, Silvi G, Macini P, Fortuna C, Venturi G, Magurano F, Fiorentini C, Marchi A, Benedetti E, Bucci P, Boros S, Romi R, Majori G, Ciufolini MG, Nicoletti L, Rezza G, Cassone A: **Chikungunya in north-eastern Italy: a summing up of the outbreak**. *Euro Surveill* 2007, **12**(47):3313.
3. Grandadam M, Caro V, Plumet S, Thiberge JM, Souares Y, Failoux AB, Tolou HJ, Budelot M, Cosserat D, Leparç-Goffart I, Despres P: **Chikungunya virus, southeastern France**. *Emerg Infect Dis* 2011, **17**(5):910–913.
4. La Ruche G, Souares Y, Armengaud A, Peloux-Petiot F, Delaunay P, Despres P, Lenglet A, Jourdain F, Leparç-Goffart I, Charlet F, Ollier L, Mantey K, Mollet T, Fournier JP, Torrents R, Leitmeyer K, Hilairat P, Zeller H, Van Bortel W, Dejour-Salamanca D, Grandadam M, Gastellu-Etchegorry M: **First two autochthonous dengue virus infections in metropolitan France, September 2010**. *Euro Surveill* 2010, **15**(39):19676.
5. Gjenero-Margan I, Aleraj B, Krajcar D, Lesnikar V, Klobucar A, Pem-Novosel I, Kurecic-Filipovic S, Komparak S, Martic R, Duricic S, Betica-Radic L, Okmadzic J, Vilbic-Cavlek T, Babic-Erceg A, Turkovic B, Avsic-Zupanc T, Radic I, Ljubic M, Sarac K, Benic N, Mlinaric-Galinovic G: **Autochthonous dengue fever in Croatia, August-September 2010**. *Euro Surveill* 2011, **16**(9):19805.
6. Sousa CA, Clairouin M, Seixas G, Viveiros B, Novo MT, Silva AC, Escoval MT, Economopoulou A: **Ongoing outbreak of dengue type 1 in the Autonomous Region of Madeira, Portugal: preliminary report**. *Euro Surveill* 2012, **17**(49):20333.
7. Hales S, De Wet N, Maindonald J, Woodward A: **Potential effect of population and climate changes on global distribution of dengue fever: An empirical model**. *Lancet* 2002, **360**(9336):830–834.
8. Vanwambeke SO, Lambin EF: **Environmental change and vector-borne diseases: The contribution of remote sensing and spatial analyses**, Vol. 1. In *Geographic Medicine, Oxford: Developed under the Auspices of the UNESCO*. Edited by Verhasselt YLG. Oxford, UK: Eolss Publishers; 2006:202–218. <http://www.eolss.net>.
9. Gould EA, Higgs S: **Impact of climate change and other factors on emerging arbovirus diseases**. *Trans R Soc Trop Med Hyg* 2009, **103**(2):109–121.
10. Straetmans M: **ECDC consultation group on vector-related risk for chikungunya virus transmission in Europe: Vector-related risk mapping of the introduction and establishment of *Aedes albopictus* in Europe**. *Euro Surveill* 2008, **13**(7):8040.
11. European Centre for Disease Prevention and Control (ECDC): *Expert consultation on guidelines for the surveillance of invasive mosquitoes*. Stockholm, 8–9 December 2011, ECDC Meeting Report. Stockholm: ECDC; 2012. <http://ecdc.europa.eu/en/publications/Publications/1203-MER-ECDC-Expert-consultation-on-mosquito-surveillance-guidelines.pdf>.
12. Reinert JF: **New classification for the composite genus *Aedes* (Diptera: Culicidae: Aedini), elevation of subgenus *Ochlerotatus* to generic rank, reclassification of the other subgenera, and notes on certain subgenera and species**. *J Am Mosq Control Assoc* 2000, **16**:175–188.
13. Reinert JF, Harbach RE, Kitching IJ: **Phylogeny and classification of *Aedini* (Diptera: Culicidae), based on morphological characters of all life stages**. *Zool J Linn Soc* 2004, **142**:289–368.
14. Reinert JF, Harbach RE, Kitching IJ: **Phylogeny and classification of *Finlaya* and allied taxa (Diptera: Culicidae: Aedini) based on morphological data from all life stages**. *Zool J Linn Soc* 2006, **148**(1):1–101.
15. JME Editorial Board: **Journal policy on names of Aedine mosquito genera and subgenera**. *J Med Entomol* 2005, **42**(4):511.
16. Savage HM, Strickman D: **The genus and subgenus categories within Culicidae and placement of *Ochlerotatus* as a subgenus of *Aedes***. *J Am Mosq Control Assoc* 2004, **20**(2):208–214.
17. Reinert JF, Harbach RE, Kitching IJ: **Phylogeny and classification of tribe *Aedini* (Diptera: Culicidae)**. *Zool J Linn Soc* 2009, **157**(4):700–794.
18. Medlock JM, Hansford KM, Schaffner F, Versteir V, Hendrickx G, Zeller H, Van Bortel W: **A review of the invasive mosquitoes in Europe: ecology, public health risks, and control options**. *Vector Borne Zoonotic Dis* 2012, **12**(6):435–447.
19. European Centre for Disease Prevention and Control (ECDC): *West Nile virus infection maps – situation update*. Stockholm: ECDC. http://www.ecdc.europa.eu/en/healthtopics/west_nile_fever/West-Nile-fever-maps/Pages/index.aspx.
20. Otranto D, Dantas-Torres F, Brianti E, Traversa D, Petric D, Genchi C, Capelli G: **Vector-borne helminths of dogs and humans in Europe**. *Parasit Vectors* 2013, **6**:16.
21. Schaffner F: *The mosquitoes and the community, Local authorities, health and environment briefing pamphlets*, no. 39. Copenhagen: WHO Regional Office for Europe; 2003.
22. Schaffner F, Medlock JM, Van Bortel W: **Public health significance of invasive mosquitoes in Europe**. *Clin Microbiol Infect* 2013, **19**:685–692.
23. Schaffner F, Chouin S, Guilloteau J: **First record of *Ochlerotatus (Finlaya) japonicus japonicus* (Theobald, 1901) in metropolitan France**. *J Am Mosq Control Assoc* 2003, **19**(1):1–5.
24. Soumahoro MK, Boelle PY, Gauzere BA, Atsou K, Pelat C, Lambert B, La Ruche G, Gastellu-Etchegorry M, Renault P, Sarazin M, Sarazin M, Yazdanpanah Y, Flahault A, Malvy D, Hanslik T: **The Chikungunya epidemic on La Reunion Island in 2005–2006: a cost-of-illness study**. *PLoS Negl Trop Dis* 2011, **5**(6):e1197.
25. Giovannini F, Mignani R: *Controllo della Zanzara-Tigre: analisi dei costi sostenuti dagli Enti Locali, Contributi*. vol. 73. Emilia-Romagna: Servizio Sanitario Regionale Emilia-Romagna; 2012:192.
26. Juliano SA, Lounibos LP: **Ecology of invasive mosquitoes: effects on resident species and on human health**. *Ecol Lett* 2005, **8**(5):558–574.
27. Schaffner F, Kaufmann C, Hegglin D, Mathis A: **The invasive mosquito *Aedes japonicus* in Central Europe**. *Med Vet Entomol* 2009, **23**(4):448–451.
28. Scott TW, Takken W: **Feeding strategies of anthrophilic mosquitoes result in increased risk of pathogen transmission**. *Trends Parasitol* 2012, **28**(3):114–121.
29. Randolph SE, Rogers DJ: **The arrival, establishment and spread of exotic diseases: patterns and predictions**. *Nat Rev Microbiol* 2010, **8**:361–371.
30. Halstead SB: **Dengue virus-mosquito interactions**. *Annu Rev Entomol* 2008, **53**:273–291.
31. European Centre for Disease Prevention and Control (ECDC): *Development of *Aedes albopictus* risk maps*, ECDC Technical Report. Stockholm: ECDC;

2009. http://www.ecdc.europa.eu/en/publications/Publications/0905_TER_Development_of_Aedes_Alboopictus_Risk_Maps.pdf.
32. European Centre for Disease Prevention and Control (ECDC): *The climatic suitability for dengue transmission in continental Europe*, ECDC Technical Report. Stockholm: ECDC; 2012. <http://ecdc.europa.eu/en/publications/Publications/TER-Climatic-suitablility-dengue.pdf>.
 33. Caminade C, Medlock JM, Ducheyne E, McIntyre KM, Leach S, Baylis M, Morse AP: **Suitability of European climate for the Asian tiger mosquito *Aedes albopictus*: recent trends and future scenarios.** *J R Soc Interface* 2012, **9**(75):2708–2717.
 34. Fischer D, Thomas SM, Niemitz F, Reineking B, Beierkuhnlein C: **Projection of climatic suitability for *Aedes albopictus* Skuse (Culicidae) in Europe under climate change conditions.** *Glob Planet Change* 2011, **78**:54–64.
 35. Ooi EE, Gubler DJ: **Global spread of epidemic dengue: the influence of environmental change.** *Future Virol* 2009, **4**(6):571–580.

doi:10.1186/1756-3305-6-209

Cite this article as: Schaffner *et al.*: Development of guidelines for the surveillance of invasive mosquitoes in Europe. *Parasites & Vectors* 2013 **6**:209.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

